Güldane CENGİZ SEVA, Pervin TOPÇUOĞLU, Taner DEMİRER

Treatment approaches for managing patients with hematological malignancies in the time of COVID-19 pandemic

Background/aim: The COVID-19 pandemic is a unique challenge to the care of patients with hematological malignancies. We aim to provide supportive guidance to clinicians making individual patients decisions during the COVID-19 pandemic, in particular during periods that access to healthcare resources may be limited. Conclusion: This review also provides recommendations, which are convenient in evaluating indications for therapy, reducing therapy-associated immunosuppression, and reducing healthcare utilization in patients with specific hematological malignancies in the COVID-19 era. Specific decisions regarding treatment of hematological malignancies will need to be individualized, based on disease risk, risk of immunosuppression, rates of community transmission of SARS-CoV-2, and available local healthcare resources.Key words: COVID-19, SARS-CoV-2, hematological malignancies

PDF

___

1- Mutnal MB, Arroliga AC, Walker K, Mohammad A, Brigmon MM et al. Early trends for SARS-CoV-2 infection in central and north Texas and impact on other circulating respiratory viruses. Journal of Medical Virology 2020; 92 (10): 2130-2138. doi: 10.1002/jmv.26010
2- Ljungman P, Mikulska M, De la Camara R, Basak GW, Chabannon C et al. European Society for Blood and Marrow Transplantation: the challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplantation 2020; 55 (11): 2071-2076.
3- Al Saleh AS, Sher T, Gertz MA. Multiple myeloma in the time of COVID-19. Acta Haematologica 2020; 143 (5): 410-416. doi: 10.1159/000507690
4- Percival MEM, Lynch RC, Halpern AB, Shadman M, Cassaday RD et al. Consideration for managing patients with hematologic malignancy during the COVID-19 pandemic: the Seattle strategy. JCO Oncology Practice 2020; 16 (9): 571-578. doi: 10.1200/OP.20.00241
5- Gavillet M, Carr Klappert J, Spertini O, Blum S. Acute leukemia in the time of COVID-19. Leukemia Research 2020; 92: 106353. doi: 10.1016/j.leukres.2020.106353
6- Paul S, Rausch CR, Jain N, Kadia T, Ravandi F et al. Treating leukemia in the time of COVID-19. Acta Haematologica 2020; 11: 1-13. doi: 10.1159/000508199
7- Demirer T, Gooley T, Buckner CD, Petersen FB, Lilleby K et al. The influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation. Bone Marrow Transplantation 1995; 15 (6): 907-913.
8- Kröger N, Damon L, Zander A R, Wandt H, Derigs G et al. Secondary acute leukemia following mitoxantrone based highdose chemotherapy for primary breast cancer patients. Bone Marrow Transplantation 2003; 32: 1153-1157. doi: 10.1038/sj.bmt.1704291
9- Zeidan AM, Boddu PC, Patnaik MM, Bewersdorf JP, Stahl M et al. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID19 era: recommendations from a panel of international experts. Lancet Haematology 2020; 7 (8): 601-612. doi:
10.1016/S2352-3026(20)30205-2 10- Brissot E, Labopin M, Baron F, Bazarbachi A, Bug G et al. Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation 2020; 11: 1-4. doi: 10.1038/s41409-020-0970-x
11- Isidori A, Leval L, Gergis U, Musto P, Porcu P. Management of patients with hematologic malignancies during the COVID-19 pandemic: practical considerations and lessons to be learned. Frontiers in Oncology 2020: 10: 1439. doi: 10.3389/fonc.2020.01439
12- Demirer T, Buckner CD, Petersen FB, Appelbaum F, Rowley S et al. Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood stem cells in patients with acute myelogenous leukemia. Bone Marrow Transplantation 1995; 15 (6): 915-922.
13- Pedrazzoli P, Ledermann JA, Lotz JP, Leyvraz S, Aglietta M et al.. High-dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. Annals of Oncology 2006; 17 (10): 1479-1488. doi: 10.1093/annonc/mdl044
14- Sahu KK, Cerny J. Managing patients with haematological malignancies during COVID-19 pandemic. Expert Review of Hematology 2020; 13 (8): 787-793. doi: 10.1080/17474086.2020.1787147
15- Perini GF, Fischer T, Gaiolla RD, Rocha TB, Bellesso M et al. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH). How to manage lymphoid malignancies during novel 2019 coronavirus (Covid-19) outbreak: a Brazilian task force recommendation. Hematology Transfusion and Cell Therapy 2020; 42 (2): 103-110. doi: 10.1016/j.htct.2020.04.002
16- Di Ciaccio P, McCaughan G, Trotman J, Ho PJ, Cheah CY et al. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. Internal Medicine Journal 2020; 50 (6): 667-679. doi: 10.1111/imj.14859
17- Brunvand MW, Appelbaum FR, Soll E, Lilleby K, Clift R et al. High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells. Bone Marrow Transplantation 1996; 18: 131-141.
18- Ueno N T, Rizzo D, Demirer T, Cheng YC, Hegenbart U et al. Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplantation 2008; 41: 537- 545. doi: 10.1038/sj.bmt.1705940
19- Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Guillaume Dighiero et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111 (12): 5446-5456. doi: 10.1182/blood-2007-06-093906.
20- Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukemia. Lancet 2018: 391 (10129): 1524-1537. doi: 10.1016/S0140-6736(18)30422-7
21- Fischer K, Bahlo J, Fink AM, Goede V, Herling CD et al. Longterm remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 2016; 127 (2): 208-215. doi: 10.1182/blood2015-06-651125
22- Treon SP, Castillo JJ, Skarbnik AP, Soumerai JD, Ghobrial IM et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood 2020; 135 (21): 1912-1915. doi: 10.1182/blood.2020006288
23- Seval GC, Beksac M. The safety of bortezomib for the treatment of multiple myeloma. Expert Opinion on Drug Safety 2018; 17 (9): 953-962. doi: 10.1080/14740338.2018.1513487
24- Al Saleh AS, Sher T, Gertz MA. Multiple myeloma in the time of COVID-19. Acta Haematologica 2020; 143 (5): 410-416. doi: 10.1159/000507690
25- Chen M, Zhao Y, Xu C, Wang X, Zhang X et al. Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. Annals of Hematology 2018; 97: 925-944. doi: 10.1007/s00277-018-3284-y
26- Basler M, Lauer C, Beck U, Groettrup M. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. Journal of Immunology 2009; 183: 6145-6150. doi: 10.4049/jimmunol.0901596
27- Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015; 100: 1254-1266. doi: 10.3324/haematol.2014.117176.
28- Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN et al. Hematological findings and complications of COVID-19. American Journal of Hematology 2020; 95 (7): 834-847. doi: 10.1002/ajh.25829
29- Terpos E, Engelhardt M, Cook G, Gay F, Mateos MV et al. Management of patients with multiple myeloma in the era of COVİD-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia 2020; 34 (8): 2000-2011. doi: 10.1038/s41375-020-0876-z
30- Mateos MV, Hernández MT, Giraldo P, De la Rubia J, De Arriba F et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. New England Journal of Medicine 2013; 369 (5): 438-447. doi: 10.1056/NEJMoa1300439
31- Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. Journal of Clinical Oncology 2020; 38 (11): 1126-1137. doi: 10.1200/JCO.19.01740
32- Kurniawan A, Halim DA, Sutandyo N. Multiple myeloma management in COVID-19 era. Asian Journal of Oncology 2021; 7 (01): 01-07. doi: 10.1055/s-0040-1716813
33- Girmenia C, Cavo M, Offidani M, Scaglione F, Corso A et al. Management of infectious complications in multiple myeloma patients: expert panel consensus-based recommendations. Blood Reviews 2019; 34: 84-94. doi: 10.1016/j.blre.2019.01.001.
34- Elens L, Langman LJ, Hesselink DA, Bergan S, Moes D et al. Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions. Therapeutic Drug Monitoring 2020; 42 (3): 360-368. doi: 10.1097/FTD.0000000000000761
35- Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug interactions on QTc in exploratory COVID-19 treatment. Journal of the American College of Cardiology 2020; 75 (20): 2623-2624. doi: 10.1016/j.jacc.2020.04.016
36- Seval GC, Topcuoglu P, Demirer T. Current approach to noninfectious pulmonary complications of hematopoietic stem cell transplantation. Balkan Medical Journal 2018; 35 (2): 131-140. doi: 10.4274/balkanmedj.2017.1635
37- Kröger N, Damon L, Zander A R, Wandt H, Derigs G et al. Secondary acute leukemia following mitoxantrone based highdose chemotherapy for primary breast cancer patients. Bone Marrow Transplantation 2003; 32: 1153-1157. doi: 10.1038/sj.bmt.1704291